Genitourinary Cancers | Specialty

Nivolumab, Cabozantinib Offer New Second-Line Options in RCC

February 15th 2016

Toni Choueiri, MD, discusses the CheckMate-025 and METEOR trials and the potential for nivolumab and cabozantinib in the first- and second-line settings for treating renal cell carcinoma.

Dr. Sharma on PD-L1 as Biomarker for Immunotherapy in Bladder Cancer

February 12th 2016

Padmanee Sharma, MD, PhD, professor of Immunology, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses PD-L1 as a predictive biomarker for immunotherapy in patients with bladder cancer.

First Urology of Louisville Enjoys Many Firsts in Technology and Research

February 9th 2016

Being the largest private practice urology center in Kentucky has its advantages, said Ganesh Rao, MD, president of First Urology, PSC, in Louisville.

Patient-Derived Xenografts Could Improve Precision Medicine Outcomes

February 6th 2016

Researchers at the UC Davis Comprehensive Cancer Center are personalizing treatment using tumor xenografts in mice to test and identify more precise treatments for bladder cancer patients.

Future Expectations in Renal Cell Carcinoma

February 4th 2016

Sequencing Metastatic Renal Cell Carcinoma Treatments

February 4th 2016

The Role of Lenvatinib and Cabozantinib in RCC

February 4th 2016

Sequencing Renal Cell Carcinoma Therapies

February 4th 2016

Managing Checkpoint Inhibitor Therapy in RCC

February 4th 2016

Study Results of Nivolumab in Renal Cell Carcinoma

February 4th 2016

Defining Disease Progression in Renal Cell Carcinoma

February 4th 2016

Combination Therapies in Renal Cell Carcinoma

February 4th 2016

Treating Non-Clear Cell Histologies of RCC

February 4th 2016

Dosing Schedule of Sunitinib in Renal Cell Carcinoma

February 4th 2016

Pazopanib and Sunitinib in Renal Cell Carcinoma

February 4th 2016

Treatment Options in Renal Cell Carcinoma

February 4th 2016

FDA Issues Complete Response Letter for Immunotherapy MCNA in Bladder Cancer

February 3rd 2016

The FDA issued a complete response letter to Telesta Therapeutics informing the company that its biologics license application for MCNA in bladder cancer would not be approved and that an additional phase III clinical trial was needed to adequately evaluate the immunotherapy.

Second-Line Cabozantinib Shows Rare Survival Advantage in RCC

February 1st 2016

The second interim analysis of the phase III METEOR trial has revealed a statistically significant improvement in overall survival with cabozantinib (Cometriq) versus everolimus as a treatment for patients with advanced renal cell carcinoma following progression on one prior therapy.

Advancing Renal Cell Carcinoma

January 29th 2016

Vaccines for Renal Cell Carcinoma

January 29th 2016